The Week in Review: Investments, Partnerships, Deals, and Earnings

In 2008, venture capital investments in China’s life science industry fell a relatively small 16% from 2007's record pace, though the numbers are distorted by a very strong Q1; Zhangjiang Hi-tech Zone announced a 1 billion RMB ($147 million) fund to support young life science companies; Agilent Technologies, the Shanghai Institutes for Biological Sciences and Tongi University collaborated to discover new insight into stem cells; Tongjitang Chinese Medicines (同济堂药业) will acquire Anhui Jingfang Pharmaceutical Co., China Biologic Products announced 2008 revenues climbed 44% to a record $46.8 million; Kun Run Biotechnology said 2008 revenues rose 56% to $11.6 million; and Tiens Biotech Group posted 2008 revenues that increased 41% to $77.2 million. More details... Stock Symbols: (NYSE: A) (NYSE: TCM) (OTCBB: CBPO) (OTCBB: KURU) (NYSE AlternextUS: TBV)